Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373901 | 0.90 | PTGS2 (0.59) | MAPK14PTGS2PTGS1 | |
| SCHEMBL5365383 | 0.88 | MAPK14 (0.57) | MAPK14PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL5368809 | 0.88 | MAPK14 (0.69) | MAPK14PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL5377634 | 0.85 | PTGS2 (0.53) | MAPK14PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL6595243 | 0.85 | MAPK14 (0.53) | MAPK14PTGS2PTGS1PDPK1 | |
| SCHEMBL6594766 | 0.85 | MAPK14 (0.49) | MAPK14PTGS2PTGS1 | |
| SCHEMBL5377150 | 0.84 | MAPK14 (0.48) | MAPK14PTGS2PTGS1 | |
| SCHEMBL5373852 | 0.83 | MAPK14 (0.48) | MAPK14PTGS2PTGS1 | |
| SCHEMBL5365336 | 0.83 | MAPK14 (0.56) | MAPK14PTGS2PTGS1CYP2C9PDPK1 | |
| SCHEMBL5368804 | 0.82 | MAPK14 (0.47) | MAPK14PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223772-B1 | Pyrazolopyridine derivatives as selective cox-2 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-29 | — | — | US | claimed |
| US-20040192694-A1 | Use of COX-2 inhibitors as gastroprokinetics | MANGEL ALLEN WAYNE (US) | 2004-09-30 | — | — | US | claimed |
| EP-1127058-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2004-09-01 | — | — | EP | claimed |
| US-6756498-B2 | REARRANGEMENT OF AZIRINE COMPOUND OR PROTECTED DERIVATIVE THEREOF IN PRESENCE OF TRANSITION METAL CATALYST AND SOLVENT TO PRODUCE PYRAZOLOPYRIDINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2004-06-29 | — | — | US | claimed |
| EP-1276742-B1 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-06-09 | — | — | EP | claimed |
| US-20030212275-A1 | PROCESS FOR THE PREPARATION OF CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2003-11-13 | — | — | US | claimed |
| JP-2003521516-A | — | — | 2003-07-15 | — | — | JP | claimed |
| US-20030022897-A1 | Use of cox-2 inhibitors as gastroprokinetics | SMITHKLINE BEECHAM CORPORATION | 2003-01-30 | — | — | US | claimed |
| EP-1276742-A2 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-01-22 | — | — | EP | claimed |
| US-20030013717-A1 | Use of cox-2 inhibitors for constipation | GLAXO GROUP LIMITED (GB) | 2003-01-16 | — | — | US | claimed |
| EP-1259239-A2 | USE OF COX-2 INHIBITORS AS GASTROPROKINETICS | GLAXO GROUP LIMITED (GB) | 2002-11-27 | — | — | EP | claimed |
| EP-1251839-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF CONSTIPATION | GLAXO GROUP LIMITED (GB) | 2002-10-30 | — | — | EP | claimed |
| WO-2001083479-A2 | PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-11-08 | — | — | WO | claimed |
| EP-1127058-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-08-29 | — | — | EP | claimed |
| WO-2001056573-A1 | USE OF COX-2 INHIBITORS AS GASTROPROKINETICS | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | claimed |
| WO-2001056555-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF CONSTIPATION | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | claimed |
| WO-2000026216-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-05-11 | — | — | WO | claimed |
| US-20070166336-A1 | Stable and palatable oral liquid sumatriptan compositions | WOCKHARDT EU OPERATIONS (SWISS) AG (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2001056573-A1 | USE OF COX-2 INHIBITORS AS GASTROPROKINETICS | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000026216-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192694-A1 | Use of COX-2 inhibitors as gastroprokinetics | PTGS2, PTGES2, PTGER2 | MAPK14 1291/4885PTGS2 1/4885PTGS1 5/4885 |
| US-20030022897-A1 | Use of cox-2 inhibitors as gastroprokinetics | PTGS2, PTGES2, PTGER2 | MAPK14 1291/4885PTGS2 1/4885PTGS1 5/4885 |
| US-20030013717-A1 | Use of cox-2 inhibitors for constipation | PTGS2, PTGES2, PTGER2 | MAPK14 1712/4885PTGS2 1/4885PTGS1 5/4885 |
| US-20030212275-A1 | PROCESS FOR THE PREPARATION OF CHEMICAL COMPOUNDS | CBR1, C1R, CBR3 | MAPK14 3024/4885PTGS2 3374/4885PTGS1 2224/4885 |
| US-20070166336-A1 | Stable and palatable oral liquid sumatriptan compositions | TAS2R39, TAS2R9, TAS2R8 | MAPK14 2282/4885PTGS2 722/4885PTGS1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.